Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

October 18th 2024

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

Dr Tang on Unanswered Questions About the Role of Radiation Therapy in RCC

October 18th 2024

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

October 15th 2024

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

October 14th 2024

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Dr Voss on the Clinical Significance of the KEYNOTE-564 Study in ccRCC

October 14th 2024

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.

Dr Voss on the Evaluation of Nivolumab/Ipilimumab in Intermediate/Poor-Risk RCC

October 11th 2024

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer

October 2nd 2024

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

October 1st 2024

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

Dr Drakaki on Nivolumab/Ipilimumab in Advanced RCC With Sarcomatoid Differentiation

September 27th 2024

Alexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.

Dr Choueiri on Initial Efficacy Data With NKT2152 in Pretreated ccRCC

September 26th 2024

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

Preliminary Data Demonstrate High CR Rate With Detalimogene in BCG-Unresponsive NMIBC With CIS

September 26th 2024

Detalimogene voraplasmid generated a 71% complete response rate in patients with BCG-unresponsive non–muscle invasive bladder cancer and CIS.

Genitourinary Oncologists Break Down Data from Lesser-Known Studies at the 2024 ESMO Congress

September 26th 2024

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Dr Drakaki on a Case Study in ALK+ Refractory Metastatic RCC

September 24th 2024

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Dr Singer on the Lack of Clinical Benefit for Immunotherapy Rechallenge in Advanced RCC

September 23rd 2024

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Dr Tang on the Current Role for Radiation Therapy in Advanced RCC

September 23rd 2024

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

September 19th 2024

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

September 19th 2024

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

September 19th 2024

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Rare Case Study of ALK+ Advanced RCC Highlights Drive for Personalized Medicine in Kidney Cancer

September 18th 2024

Alexandra Drakaki, MD, dives into a case study of a patient with ALK-positive RCC that exemplified the importance of NGS and precision medicine in kidney cancer.